Neurofibromatosis type 1

The PBS subsidises selumetinib for patients with neurofibromatosis type 1.

Please note: You’ll get an immediate assessment when you request PBS authorities online.

Patient eligibility

The Pharmaceutical Benefits Scheme (PBS) subsidises treatment with selumetinib under the National Health Act 1953, section 85 for patients with neurofibromatosis type 1.

Patients must be eligible for the PBS and meet the relevant restriction criteria.

The Schedule of Pharmaceutical Benefits on the PBS website outlines the restrictions for prescribing selumetinib.

Treatment specifics

To be eligible for PBS-subsidised treatment with selumetinib, patients must be treated by either a:

  • specialist physician with expertise in neurofibromatosis
  • medical practitioner in consultation with a specialist physician with expertise in neurofibromatosis, if attendance isn’t possible due to geographic isolation.

Authority applications

Applying for initial treatment

Applications for initial authority approval to prescribe PBS-subsidised selumetinib to treat neurofibromatosis type 1 can be made either in:

All written applications must include:

Applying for initial grandfather treatment

Applications for initial grandfather authority approval to prescribe PBS-subsidised selumetinib to treat neurofibromatosis type 1 can be made either in:

All written applications must include:

Applying for continuing treatment

Applications for continuing authority approval to prescribe PBS-subsidised selumetinib to treat neurofibromatosis type 1 can be made either:

More information

Call the PBS Complex Drugs Programs enquiry line for more information.

Page last updated: 1 August 2024.
QC 74412